Methods of treatment using a syringe extrusion accessory

Information

  • Patent Grant
  • 11684719
  • Patent Number
    11,684,719
  • Date Filed
    Friday, July 12, 2019
    4 years ago
  • Date Issued
    Tuesday, June 27, 2023
    10 months ago
Abstract
A method of treatment may include providing a syringe having medicinal fluid therein for administering to a patient and coupling an attachment portion of an extrusion accessory having a handle and a pawl to a flange portion of the syringe. The pawl may have first and second ends, and be hingedly and rotatably coupled relative to the handle at a first position at the first end and at a second position between the first and second ends. The method may further include applying a force to translate the handle in a direction substantially perpendicular relative to a longitudinal axis of the syringe to cause axial movement of the second end of the pawl. The second end of the pawl may be engaged with a plunger of the syringe and axial movement of the second end of the pawl may drive the plunger forward to extrude the medicinal fluid from the syringe.
Description
TECHNICAL FIELD

The present invention generally relates to methods of treatments using medical injection device accessories, and more specifically relates to methods of treatment using a medical syringe extrusion accessory designed to facilitate aliquot dosing.


BACKGROUND

The ability to accurately assess correct injection dosage is most commonly associated with visual cues. For example, volumetric marks already come printed or etched on the side of conventional syringe bodies, and this remains the most common form of measurement. A practitioner injects a certain amount of a substance, such as a drug, by verifying fluid level using these volumetric marks.


Even more generally, a physician can intake an amount of a drug to be injected into the syringe using the volumetric marks. Then, a practitioner can simply expel the entire volume into a patient in a single plunger run. Such a full expulsion of drug removed the need to only inject a portion of a drug in a syringe. Thus, for pharmaceutical drugs, the benefits of injecting the correct dosage should not require explanation.


However, in applications using sensitive drugs such as botulinum toxin or aesthetic soft tissue fillers, for example, hyaluronic acid-based dermal fillers such as Juvederm® XC, manufactured by Allergan, Inc., dose indication provides the practitioner with additional control over precise facial sculpting.


Additionally, with applications like botulinum toxin, injection of multiple small, precise doses of toxin may be advantageous over injection of a large bolus of the material.


Further, with fat grafting, injection of multiple small, precise doses of fat cell-containing material may be advantageous over injection of a single large bolus of the material. Smaller bolus injection increases retention of the injected material, possibly by providing greater vascularization of the material throughout the fat cells and improving survivability thereof. Injection of a large bolus is less likely to be retained long term as the injected fat cells are may be more prone to die, due to lack of vascularization, for example.


Many of these injectable materials, for example, dermal fillers and fat grafting materials, are not easily extruded through standard syringes and accompanying cannula. These materials tend to provide significant resistance to be pushed through a narrow cannula. The problem is even more exacerbated by the fact that these materials are often used for detailed precision work in facial contouring and body sculpting.


Injection devices, both manual and motorized, have been specifically developed, or at least proposed, to address these issues. Interestingly, many physicians prefer the use of manual conventional syringe injectors over electronically controlled, motorized devices. For at least this reason, there remains a need for devices (e.g., simple devices) that can be attached to a standard syringe and which provide better control over small aliquot dosing of relatively difficult to inject materials, for example, dermal fillers, fat grafting materials and the like.


The description provided in the background section should not be assumed to be prior art merely because it is mentioned in or associated with the background section. The background section may include information that describes one or more aspects of the subject technology.


SUMMARY

Disclosed herein are mechanical dosing accessories and/or syringe extrusion accessories configured to be attached to, coupled to, or incorporated into standard syringes. The dosing accessories are configured to provide improved mechanical advantage or leverage and dosing capability, relative to a conventional syringe alone. In some embodiments, the accessories described can be used in conjunction with conventional syringes for injection of substances. The substances or products can be highly viscous such as, but not limited to, dermal fillers or fat grafting materials.


Various embodiments of the present disclosure are directed to methods of treatment using syringe extrusion accessories. The method may include providing a syringe having a medicinal fluid therein for administering to a patient, and coupling an attachment portion of an extrusion accessory having a handle and a pawl to a flange portion of the syringe. The handle may be hingedly coupled to the attachment portion. The pawl may have first and second ends, and be hingedly and rotatably coupled relative to the handle at a first position at the first end and at a second position between the first and second ends. The method may further include applying a force to translate the handle in a direction that is substantially perpendicular relative to a longitudinal axis of the syringe to cause axial movement of the second end of the pawl. The second end of the pawl may be engaged with a plunger of the syringe and axial movement of the second end of the pawl drives the plunger forward to extrude the medicinal fluid from the syringe.


In some embodiments, a method of dispensing a medicinal fluid in a predetermined dosage for treatment of a patient may include applying a force to translate a handle of an extrusion accessory, coupled to a syringe, in a direction that is substantially perpendicular relative to a longitudinal axis of the syringe. The extrusion accessory may include a pawl having first and second ends and may be hingedly and rotatably coupled relative to the handle at the first end of the pawl and at a position between the first and second ends. The application of force to the handle may move the second end of the pawl for engaging with and pushing a plunger of the syringe axially for extruding the medicinal fluid from the syringe.


It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the subject technology as claimed. It is also to be understood that other aspects may be utilized, and changes may be made without departing from the scope of the subject technology.





BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the present description are illustrated by way of example, and not by way of limitation, in the figures of the accompanying drawings and in which like reference numerals refer to similar elements, wherein:



FIG. 1 illustrates a perspective view of a syringe and a syringe extrusion accessory as described herein.



FIG. 2 illustrates a perspective view of a syringe with an extrusion accessory as illustrated in FIG. 1 attached thereto.



FIG. 3 illustrates a first step in using an extrusion accessory wherein the accessory is added to the syringe and prepared for use.



FIG. 4 illustrates a second step in using an extrusion accessory wherein a substantially perpendicular force is applied to the accessory's handle thereby applying an axial force to the syringe's plunger.



FIG. 5 illustrates a third step in using an extrusion accessory wherein a substantially perpendicular force is applied to the accessory's handle until the pawl can no longer extend from the handle indicating the end of an injection sequence.



FIG. 6 illustrates a reset of the extrusion accessory to extrude a further amount of substance from the syringe.





DETAILED DESCRIPTION

Generally described are syringe accessories such as, but not limited to mechanical dosing accessories and/or syringe extrusion accessories that can be attached to a conventional syringe and provide a transfer of perpendicular force to axial force for injection. In other embodiments, an accessory as described herein can be permanently mounted to a syringe using, for example, glue or adhesive. In still other embodiments, a syringe including an accessory as described herein can be produced as a single integrated device.


As illustrated in FIGS. 1-2, an accessory 100 as described herein can generally include handle 102, pawl 104, attachment portion 106, a first hinge 108 and a second hinge 110.


Handle 102 can optionally include a finger indentation region 112 wherein a user can apply a substantially perpendicular force to a depressed portion thereby focusing the force to a substantially predetermined point on handle 102. Handle 102 can be configured to accept a substantially perpendicular input force and transfer that force to pawl 104.


Pawl 104 is operably attached to handle 102 through second hinge 110. Pawl 104 can have a generally sinusoidal shape having a first end 114 terminating at second hinge 110 and second end 116 terminating at one or more claws 118. First end 114 can be curved toward the proximal end 130 of syringe 122 when fully extended in use thereby achieving the translation of force provided by the accessories. Second end 116 can be curved toward the distal end of syringe 122 when fully extended in use.


Pawl 104 can be operably configured to move one or more claws 118 in generally axial direction 120. Pawl 104 can include one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, 13, 14, 15, 16, 17, 18, 19, 20, or more claws. As such, based on substantially perpendicular movement of handle 102, claws 118 can in turn be moved in axial direction 120 through second hinge 110.


Further, handle 102 is operably connected to attachment portion 106 through first hinge 108. Attachment portion 106 is configured to allow attachment of accessory 100 to syringe 122. In one embodiment, accessory 100 can be attached to syringe 122 at flange 124. Attachment portion 106 can be shaped to at least partially engage flange 124. In some embodiments, attachment portion 106 can engage between about 20% and about 80%, between about 30% and about 60%, between about 40% and about 60%, between about 50% and about 70%, or between about 60% and about 80% of flange 124. Attachment portion 106 can engage with flange 124 using a friction fit, a locking fit where attachment portion 106 includes locking features that snap and lock once the two parts are engaged, or a glue engagement wherein attachment portion 106 and flange 124 are glued together.


Substantially perpendicular force applied to handle 102 can be translated to force in axial direction 120. Claws 118 can engage plunger 126 and provide an axial force thereby driving plunger head 128 toward proximal end 130 of syringe 122.


Substantially perpendicular force can be applied at an angle 132 which is substantially perpendicular to syringe 122. Angle 132 can be about 1 degree, about 5 degrees, about 10 degrees, about 15 degrees, about 20 degrees, about 25 degrees, less than about 5 degrees, less than about 10 degrees, less than about 15 degrees, between about 1 degree and about 10 degrees, between about 1 degree and about 20 degrees, or between about 5 degrees and about 25 degrees.


This substantially perpendicular force can replace axial forces that typically must be applied to plunger finger surface 134. With highly viscous materials such as dermal fillers and fat grafting substances, substantial axial forces must be applied in order to extrude these materials from a needle or other delivery device attached to luer tip 136 or other attachment interface. This need to apply a substantial force to plunger finger surface 134 requires a user to balance applying axial forces to the syringe with resisting axial forces of a needle into the tissue.


In some embodiments, luer tip 136 or other attachment interface can be configured to attach to a cannula or needle which is suitable for introducing contents of syringe 122 into a target region of a patient for tissue bulking, augmentation or reconstructive purposes.


In other embodiments, luer tip 136 or other attachment interface can be configured to attach to flexible tubing or a conduit which is suitable for introducing contents of syringe 122 into a target region of a patient for tissue bulking, augmentation or reconstructive purposes. Such embodiments may allow for enhanced flexibility and ergonomic grip of a cannula or a needle.


A cannula or a needle as used herein can be a 10, 12, 14, 16, 18, 20, 22 up to 33 gauge, or other gauges. In some embodiments, the needle gauge may be one suitable for fat grafting or dermal filler purposes. In one embodiment, the needle gauge is between 10 and 33. The length of a needle can be any appropriate length known in the art. In one embodiment, the needle length is about 1/16 inch to about 3 inches, more generally about 1/16 inch to about 2 inches. A cannula or a needle may be blunt or sharp tipped.


Pawl 104 can be configured to engage with a given plunger style. Plungers can have various shapes for stem portion 138. For example, as illustrated in the Figures, stem 138 includes vertical appendage 140 and horizontal appendage 142. Thus, in one embodiment, pawl 104 can be split at second end 116 thereby straddling vertical appendage 140 without touching it and engaging both sides of horizontal appendage 142.


In other embodiments, stem portion 138 may have a cylindrical shape or circular cross-section. In such embodiments, pawl 104 can have a single second end 116 or an un-split second end. This single second end 116 can engage stem portion 138 along its cylindrical surface.


Various other stem shapes can be used and skilled artisans will understand how to modify pawl 104 to engage these types of plungers and translate substantially perpendicular force to axial force on the plunger.


In some embodiments, spring 144 can be provided to couple pawl 104 to handle 102 as illustrated in FIGS. 3-6. Spring 144 can provide a resistive or compressive force as handle 102 is depressed. When handle 102 is disengaged, thereby disengaging pawl 104 from plunger 126, spring 144 can compress thereby pulling pawl 104 toward handle 102 as illustrated in FIG. 6 thereby “re-setting” the device.


In some embodiments, tracks can be provided on plunger 126 for claws 118 to engage. For example, as illustrated in FIG. 5, in some embodiments, tracks 146 can be located on vertical appendage 140 and/or horizontal appendage 142.


An exemplary track system can be configured to allow claws 118 to engage in one or more valleys 150 between adjacent teeth 148. In some embodiments, teeth 148 can have a generally rounded or oval surface preventing claw leverage onto the plunger. Each valley 150 between adjacent teeth 148 can be spaced a predetermined distance 152 from the next valley 150.


In other embodiments, teeth 148 can be configured to have a generally wave-like shape. When a claw is engaged in a valley 150 with a long front surface and a short back surface, claws 118 can provide force against the short wall of teeth 148. In some embodiments, an accessory 100 can include a plunger that has tracks that can be used with accessory 100. When a plunger is provided, the syringe plunger can be replaced with the provided plunger.


In other embodiments, a track or set of tracks can be provided to be attached to a plunger. In these embodiments, tracks can be glued to the plunger stem prior to use. In other embodiments, tracks can be snapped around a plunger stem.


Each valley 150 between adjacent ratcheting teeth 148 can be spaced 152 from the next valley. Each space 152 can be equivalent to a predetermined amount of substance ejected from the syringe. This is the case because movement of track 146 a particular distance moves plunger 126 which eventually moves plunger head 128 the same axial distance.


Accessory 100 can be formed of metal, a polymer, or a combination thereof. In some embodiments, accessory 100 can include materials such as, but not limited to, rigid thermoplastics, thermoplastic elastomers, silicones, glass, metals, composite materials, carbons fillers, or any combination thereof.


The accessories described herein can allow an operator to easily inject viscous substances or materials through any size needle known in the art by applying substantially perpendicular force to the handle. The accessories make the syringe easy to hold, manipulate and operate with one hand, and in some cases adjust easily with the operator's opposing hand. The accessories can allow the operator to precisely control the injection speed (or extrusion rate) being injected. The accessories can also allow an operator to still see the graduation or volume markings on the syringe body thereby allowing an operator to visualize initial volume, volume injected and remaining volume of substance in the syringe.


Further, the accessories described herein can have an ergonomic shape that allows the operator to hold and inject from the syringe easily. Unlike traditional syringes which do not conform to any ergonomic aspect of the hand, the present devices can have at least one ergonomic design shaped into the accessories such as finger indentation region 112. Additionally, the present accessories can accommodate operator hands of different sizes. Hand size accommodation can be accomplished by different device sizes, position-adjustable device handles or interchangeable device handles. For example, interchangeable handles can come in various predetermined sizes or can be personalized for a particular user.


Methods of using the accessories described are also contemplated. For example, in some embodiments, an accessory is provided and attached to a syringe preferably at the syringe flange 124 as illustrated in FIG. 3. Spring 144 can be configured to rest handle 102 at a predetermined angle 132 relative to syringe 122 with claws 118 resting against plunger stem 138.


Then, as illustrated in FIG. 4, force is applied to handle 102 substantially perpendicular to syringe 122, thereby driving axial force to plunger 126 as translated by pawl 104.


When a particular spring force has been exhausted or a stop 154 on the underside of handle 102 has been reached, plunger 126 will not be moved axially any further as illustrated in FIG. 5. At this point, a full extension of accessory 100 has been achieved.


In other embodiments, full extension of accessory 100 can be achieved when pawl 104 abuts handle 102 at leading edge 162.


The force applied to move from predetermined angle 132 illustrated in FIG. 3 to the full extension of accessory 100 in FIG. 5 can translate into a predetermined dose of extruded content. For example, the force can translate into about 0.1 mL, about 0.5 mL, about 1 mL, about 2 mL, about 3 mL, about 4 mL, about 5 mL, about 10 mL, about 15 mL, about 20 mL, between about 0.1 mL and about 10 mL, between about 1 mL and about 10 mL, or between about 0.5 mL and about 5 mL. In other embodiments, a second stop 156 can be supplied such that pawl 104 can only travel between second stop 156 and stop 154. This distance of pawl 104 travel can be equivalent to an extruded amount from syringe 122.


For example, in some embodiments, predetermined distance 152 can define a dosage of substance because predetermined distance 152 can cause axial movement of plunger head 128 a second pre-determined distance 160. This second pre-determined distance 160 in turn represents a particular volume of substance extruded from syringe 122.


In other embodiments, the use of accessory 100 may not deliver a predetermined amount of substance or material but rather the amount delivered may still require use of visual marks on syringe 122.


In any circumstance, whether pre-determined or manual delivery amounts, once full extension of accessory 100 is achieved, claws 118 can be disengaged from plunger 126 by pulling handle 102 upward and away from syringe 122 as illustrated in FIG. 6. This disengagement can “re-set” the accessory to reengage the plunger 126 and deliver a subsequent dose of substance or material.


In some embodiments, when spring 144 is used, the upward force 158 needed to disengage claws 118 from plunger 126 can be reduced. Also, using spring 144 can pull pawl 104 toward handle 102 thereby “re-setting” accessory 100 for subsequent delivery.


Kits including an accessory as described herein are also contemplated. A kit can include an accessory that is configured to be attached to a syringe and instructions for use. In other embodiments, a kit can include an accessory, a syringe and instructions for use. In still other embodiments, a kit can include an accessory, a syringe filled with an injectable substance or a separate vial including the substance, and instructions for use. In other embodiments, a kit can include a syringe including an integrated accessory. In other embodiments, a kit can include a syringe including an integrated accessory and an injectable substance within the syringe or in a vial in the kit.


Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.


The terms “a,” “an,” “the” and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.


Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.


Certain embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.


Furthermore, numerous references have been made to patents and printed publications throughout this specification. Each of the above-cited references and printed publications are individually incorporated herein by reference in their entirety.


Specific embodiments disclosed herein may be further limited in the claims using consisting of or and consisting essentially of language. When used in the claims, whether as filed or added per amendment, the transition term “consisting of” excludes any element, step, or ingredient not specified in the claims. The transition term “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s). Embodiments of the invention so claimed are inherently or expressly described and enabled herein.


In closing, it is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.

Claims
  • 1. A method of treatment comprising: providing a conventional syringe having a medicinal fluid therein for administering to a patient, the conventional syringe comprising a cylindrical body, a flange portion extending radially outwardly from the cylindrical body at a distal portion thereof, and a plunger reciprocally disposed within the cylindrical body;coupling an attachment portion of an extrusion accessory to the flange portion of the syringe, the extrusion accessory having a handle hingedly coupled to the attachment portion and a pawl having first and second ends, the pawl being hingedly and rotatably coupled relative to the handle at a first position at the first end and via a pawl-coupling, at a second position between the first and second ends;applying a force to translate the handle in a direction that is substantially perpendicular relative to a longitudinal axis of the syringe to cause axial movement of the second end of the pawl, wherein the second end of the pawl is engaged with the plunger of the syringe and axial movement of the second end of the pawl drives the plunger forward to extrude the medicinal fluid from the cylindrical body of the syringe; andpermitting the pawl and the handle to be repositioned by foreshortening of the pawl-coupling between the pawl and the handle such that the pawl is pulled towards the handle.
  • 2. The method of claim 1, wherein the pawl includes a claw positioned at the second end thereof and the plunger includes a stem portion, and the applying comprises engaging the claw with the stem portion.
  • 3. The method of claim 2, wherein the stem portion comprises a vertical appendage and a horizontal appendage, and wherein during the applying, the claw engages the vertical appendage or the horizontal appendage to provide an axial force to drive the plunger towards a proximal end of the syringe.
  • 4. The method of claim 3, wherein the pawl includes a split at the second end thereof, wherein during the applying, opposing sides of the horizontal appendage are engaged with corresponding opposing sides of the split of the pawl while straddling without contacting the vertical appendage.
  • 5. The method of claim 4, wherein at least one of the horizontal appendage or the vertical appendage comprise a set of tracks including pairs of adjacent teeth each interposed by a valley therebetween, the valleys each being spaced apart a predetermined distance, and wherein the applying comprises translating the handle to move the pawl along the predetermined distance to extrude a predetermined dosage of the medicinal fluid from the syringe.
  • 6. The method of claim 2, wherein the stem portion comprises a vertical appendage and a horizontal appendage, and the applying comprises engaging the claw with the horizontal appendage to provide an axial force to drive the plunger towards a proximal end of the syringe.
  • 7. The method of claim 1, wherein the pawl is coupled to the handle through a hinge at the first end, the pawl having a generally sinusoidal shape with the first end terminating at the hinge, and wherein during the applying, the first end curves towards a proximal end of the syringe when the first end is in a fully extended position in use so as to translate the substantially perpendicular force to the axial movement.
  • 8. The method of claim 1, wherein a proximal end of the syringe comprises a luer tip attached to a cannula or a needle, the method further comprising introducing the medicinal fluid from the syringe, through the cannula or the needle, into a target region of a patient for tissue bulking, augmentation or reconstructive purposes.
  • 9. The method of claim 8, wherein the introducing is performed for fat grafting or dermal filler purposes.
  • 10. The method of claim 1, wherein the pawl-coupling couples the pawl to the handle at the second position through a compression spring.
  • 11. The method of claim 1, wherein the applying comprises applying the substantially perpendicular force at an angle of between about 1 degree and about 20 degrees relative to a line normal to the longitudinal axis of the syringe.
  • 12. The method of claim 1, wherein coupling the extrusion accessory to the syringe comprises attaching the attachment portion to the flange portion of the syringe by a snap fit, a friction fit, a glue, an adhesive, or a combination thereof.
  • 13. A method of dispensing a medicinal fluid in a predetermined dosage for treatment of a patient, the method comprising applying a force to translate a handle of an extrusion accessory, coupled to a conventional syringe, in a direction that is substantially perpendicular relative to a longitudinal axis of the syringe, the syringe comprising a cylindrical body in which the medicinal fluid is disposed, a flange portion extending radially outwardly from the cylindrical body at a distal portion thereof, and a plunger reciprocally disposed within the cylindrical body, the extrusion accessory comprising a pawl having first and second ends and being hingedly and rotatably coupled relative to the handle at the first end of the pawl and via a pawl-coupling at a second position between the first and second ends, wherein application of force to the handle moves the second end of the pawl for engaging with and pushing the plunger of the syringe axially for extruding the medicinal fluid from the cylindrical body of the syringe, and wherein releasing the force on the handle permits the pawl and the handle to be repositioned by action of the pawl-coupling between the pawl and the handle such that the pawl is pulled towards the handle.
  • 14. The method of claim 13, wherein the pawl includes a claw positioned at the second end thereof and the plunger includes a stem portion, the engaging the second end of the pawl with the plunger comprising engaging the claw with the stem portion.
  • 15. The method of claim 14, wherein the stem portion comprises a vertical appendage and a horizontal appendage, and wherein the applying comprises engaging the claw with the vertical appendage or the horizontal appendage to provide an axial force to drive the plunger towards a proximal end of the syringe.
  • 16. The method of claim 13, wherein the syringe comprises a luer tip attached to a cannula or needle, and wherein the applying comprises extruding the predetermined dosage of medicinal fluid from the syringe by pushing the plunger to introduce the medicinal fluid through the needle from the syringe and into a target region of a patient for tissue bulking, augmentation or reconstructive purposes.
  • 17. The method of claim 16, wherein the needle has a gauge sized for fat grafting or dermal filler purposes.
  • 18. The method of claim 17, wherein the applying comprises applying the substantially perpendicular force at an angle of between about 1 degree and about 20 degrees relative to a line normal to a longitudinal axis of the syringe.
  • 19. The method of claim 13, wherein the pawl-coupling couples the pawl to the handle at the second position through a compression spring, the method further comprising permitting the pawl and handle to be urged to a reset position via action of the spring-coupling such that the pawl is pulled towards the handle.
  • 20. An extrusion accessory for a conventional syringe, the accessory comprising: an attachment portion couplable to a flange portion of the conventional syringe; a handle hingedly coupled to the attachment portion; anda pawl having first and second ends, the pawl being hingedly and rotatably coupled relative to the handle at a first position at the first end and at a second position, via a pawl-coupling, between the first and second ends such that application of force to the handle moves the second end of the pawl for engaging with and pushing plunger of the syringe axially for extruding the medicinal fluid from the cylindrical body of the syringe, and releasing the force on the handle permits the pawl and the handle to be repositioned by action of the pawl-coupling between the pawl and the handle such that the pawl is pulled towards the handle.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/011,897, filed Feb. 1, 2016, which is a continuation of U.S. patent application Ser. No. 14/284,285, filed May 21, 2014, which claims the benefit of U.S. Provisional Patent App. No. 61/826,878, filed May 23, 2013, the entire disclosure of each of which is incorporated herein by this specific reference.

US Referenced Citations (378)
Number Name Date Kind
977282 De Vilbiss Nov 1910 A
1250114 Bigelow et al. Dec 1917 A
1558037 Morton Oct 1925 A
1591021 Davis Jul 1926 A
2007140 Ragnar Jul 1935 A
2302986 Vollrath Nov 1942 A
2491978 Helfman Dec 1949 A
2551902 Rieck May 1951 A
2737946 Hein, Jr. Mar 1956 A
2853070 Julliard Sep 1958 A
3086530 Groom Apr 1963 A
3161323 Bent Dec 1964 A
D202754 Fnftolin Nov 1965 S
D214112 Langdon May 1969 S
3517668 Brickson Jun 1970 A
3595231 Pistor Jul 1971 A
D224066 McDonald Jun 1972 S
3720211 Kyrias Mar 1973 A
3767085 Cannon et al. Oct 1973 A
3807048 Malmin Apr 1974 A
3910282 Messer et al. Oct 1975 A
3916777 Earl Nov 1975 A
3977574 Thomas Aug 1976 A
4064879 Leibinsohn Dec 1977 A
4240423 Akhavi Dec 1980 A
4240426 Akhavi Dec 1980 A
4273122 Whitney et al. Jun 1981 A
4326517 Whitney et al. Apr 1982 A
4346708 Leeven Aug 1982 A
4444560 Jacklich Apr 1984 A
4529401 Leslie et al. Jul 1985 A
4581022 Leonard Apr 1986 A
4617016 Blomberg Oct 1986 A
4624659 Goldberg Nov 1986 A
4671255 Dubrul et al. Jun 1987 A
4693684 Blatherwick Sep 1987 A
4695273 Brown Sep 1987 A
4699612 Hamacher Oct 1987 A
4710172 Jacklich Dec 1987 A
4710178 Henri Dec 1987 A
4719918 Bonomo et al. Jan 1988 A
4755169 Sarnoff Jul 1988 A
4759750 Devries Jul 1988 A
4779770 Herold Oct 1988 A
4800901 Rosenberg Jan 1989 A
4832692 Box May 1989 A
4841948 Bauser et al. Jun 1989 A
4841992 Sasaki et al. Jun 1989 A
4846886 Fey et al. Jul 1989 A
D303010 Jabbusch Aug 1989 S
4869717 Adair Sep 1989 A
4908029 Bark et al. Mar 1990 A
4955905 Reed Sep 1990 A
4957744 dellaValle et al. Sep 1990 A
5019053 Hoffman May 1991 A
5024656 Gasaway et al. Jun 1991 A
5046506 Singer Sep 1991 A
5066303 Bark et al. Nov 1991 A
5092348 Dubrul et al. Mar 1992 A
5100390 Lubeck et al. Mar 1992 A
5104375 Lubeck et al. Mar 1992 A
5116358 Granger et al. May 1992 A
5127436 Campion et al. Jul 1992 A
5141496 Dalto et al. Aug 1992 A
5211644 VanBeek et al. May 1993 A
5258013 Granger et al. Nov 1993 A
5270685 Hagen Dec 1993 A
5279544 Gross Jan 1994 A
5295980 Ersek Mar 1994 A
5305788 Mayeux Apr 1994 A
5318544 Drypen Jun 1994 A
5322511 Armbruster et al. Jun 1994 A
5344407 Ryan Sep 1994 A
5354279 Hofling Oct 1994 A
5368572 Shirota Nov 1994 A
5383851 Mackinnon, Jr. Jan 1995 A
5405330 Zunitch et al. Apr 1995 A
5433352 Ronvig Jul 1995 A
5478327 McGregor et al. Dec 1995 A
5540657 Kurjan Jul 1996 A
5549672 Maddock et al. Aug 1996 A
5611809 Marshall et al. Mar 1997 A
D378939 Smith et al. Apr 1997 S
5690618 Smith et al. Nov 1997 A
5752970 Yoon May 1998 A
5807340 Pokras Sep 1998 A
5817033 DeSantis Oct 1998 A
5823998 Yamagata Oct 1998 A
5824335 Dorigatti et al. Oct 1998 A
5846225 Rosengart et al. Dec 1998 A
5891106 Butuzov Apr 1999 A
5941845 Tu et al. Aug 1999 A
5964737 Caizza Oct 1999 A
D424194 Holdaway et al. May 2000 S
6077251 Ting et al. Jun 2000 A
6102929 Conway et al. Aug 2000 A
6159233 Matsuzawa Dec 2000 A
6171276 Lippe Jan 2001 B1
6183434 Eppstein Feb 2001 B1
D441077 Garito et al. Apr 2001 S
6231552 Jentzen May 2001 B1
6231570 Tu et al. May 2001 B1
6283951 Flaherty et al. Sep 2001 B1
6293925 Safabash et al. Sep 2001 B1
6303518 Aceti Oct 2001 B1
6312412 Saied Nov 2001 B1
6432046 Yarush et al. Aug 2002 B1
6451240 Sherman et al. Sep 2002 B1
6482187 Gibbs Nov 2002 B1
6488651 Morris Dec 2002 B1
6551290 Elsberry et al. Apr 2003 B1
6595960 West et al. Jul 2003 B2
6607512 Oliver Aug 2003 B2
6607513 Down Aug 2003 B1
6611707 Prausnitz et al. Aug 2003 B1
6613010 Castellano Sep 2003 B2
6616448 Friedman Sep 2003 B2
D483116 Castellano Dec 2003 S
6689095 Garitano et al. Feb 2004 B1
6689103 Palasis Feb 2004 B1
6780171 Gabel Aug 2004 B2
6783514 Tovey et al. Aug 2004 B2
6824526 Castellano Nov 2004 B2
6896666 Kochamba May 2005 B2
6901850 Corominas Jun 2005 B2
6908453 Fleming Jun 2005 B2
6936297 Roby et al. Aug 2005 B2
6945952 Kwon Sep 2005 B2
7004928 Aceti Feb 2006 B2
7018356 Wise et al. Mar 2006 B2
7033337 Hjertman Apr 2006 B2
7041088 Nawrocki et al. May 2006 B2
7047070 Wilkinson et al. May 2006 B2
7048729 Meglin et al. May 2006 B2
7097631 Trautman Aug 2006 B2
7108681 Gartstein Sep 2006 B2
7115108 Wilkinson et al. Oct 2006 B2
7150726 Dalton Dec 2006 B2
7302885 Townsend Dec 2007 B2
7361163 Cohen Apr 2008 B2
7419472 Hibner et al. Sep 2008 B2
7442187 Khayal et al. Oct 2008 B2
7494473 Eggers et al. Feb 2009 B2
7504386 Pressato et al. Mar 2009 B2
7556615 Pettis et al. Jul 2009 B2
7559952 Pinchuck Jul 2009 B2
7588547 Deem Sep 2009 B2
7611495 Gianturco Nov 2009 B1
7651475 Angel Jan 2010 B2
7662110 Flaherty Feb 2010 B2
7664545 Westersten et al. Feb 2010 B2
7666339 Chaouk et al. Feb 2010 B2
D615192 Mudd et al. May 2010 S
7722582 Lina et al. May 2010 B2
7762983 Arnissolle Jul 2010 B2
7850656 McKay et al. Dec 2010 B2
7850683 Elkins Dec 2010 B2
7878981 Strother et al. Feb 2011 B2
7896837 Wilkinson et al. Mar 2011 B2
D637287 Mudd et al. May 2011 S
7998170 Cunningham Aug 2011 B2
8012139 McKay et al. Sep 2011 B2
8029460 Rush et al. Oct 2011 B2
8066629 Dlugos Nov 2011 B2
8083722 McKay et al. Dec 2011 B2
8088108 Kraft Jan 2012 B2
8157830 Wenchell Apr 2012 B2
8172815 Down et al. May 2012 B2
8216190 Gartstein Jul 2012 B2
8236021 Kluge Aug 2012 B2
8291768 Spiegel Oct 2012 B2
8303518 Aceti Nov 2012 B2
8303545 Schraga Nov 2012 B2
8343132 Heneveld et al. Jan 2013 B2
8349554 Bahrami et al. Jan 2013 B2
8353871 Zimmerman Jan 2013 B2
8366643 Deem Feb 2013 B2
8394118 Jones et al. Mar 2013 B2
8409147 Kraft Apr 2013 B2
8409185 Burger Apr 2013 B2
8480630 Mudd et al. Jul 2013 B2
8535278 Mudd et al. Sep 2013 B2
8562571 Mudd et al. Oct 2013 B2
8603028 Mudd et al. Dec 2013 B2
8632501 Kraft Jan 2014 B2
8636797 Chitre et al. Jan 2014 B2
8657786 Bahrami et al. Feb 2014 B2
8668675 Chase Mar 2014 B2
8708965 Boyden Apr 2014 B2
8712815 Nichols et al. Apr 2014 B1
8821446 Trautman Sep 2014 B2
8900181 Knowlton Dec 2014 B2
8900186 Pettis et al. Dec 2014 B2
8945060 Bunch Feb 2015 B2
9017289 Backes Apr 2015 B2
9017318 Fourkas Apr 2015 B2
9039688 Palmer, III May 2015 B2
9066712 Fourkas Jun 2015 B2
9072498 Elkins Jul 2015 B2
9101346 Burger Aug 2015 B2
9113855 Burger Aug 2015 B2
9149331 Deem Oct 2015 B2
9155584 Fourkas Oct 2015 B2
9180273 Konstantino Nov 2015 B2
9214030 Sole et al. Dec 2015 B2
9227023 Kraft Jan 2016 B2
9241753 Fourkas Jan 2016 B2
9254162 Burger Feb 2016 B2
9289605 Choi Mar 2016 B2
9314568 Gurtner et al. Apr 2016 B2
9468748 Bang Oct 2016 B2
20010008937 Callegaro et al. Jul 2001 A1
20020010433 Johnson Jan 2002 A1
20020026039 Bellini et al. Feb 2002 A1
20020065483 Leon May 2002 A1
20020133114 Itoh Sep 2002 A1
20020151843 Correa et al. Oct 2002 A1
20030028154 Ros Feb 2003 A1
20030050602 Pettis et al. Mar 2003 A1
20030078912 Oliver Apr 2003 A1
20030144632 Hommann et al. Jul 2003 A1
20030181863 Ackley Sep 2003 A1
20030199883 Laks Oct 2003 A1
20040010224 Bodmeier Jan 2004 A1
20040015133 Karim Jan 2004 A1
20040092927 Podhajsky et al. May 2004 A1
20040147883 Tsai Jul 2004 A1
20040192643 Pressato et al. Sep 2004 A1
20040220532 Caizza Nov 2004 A1
20050033362 Grafton Feb 2005 A1
20050085767 Menassa Apr 2005 A1
20050131353 Mossanen-Shams et al. Jun 2005 A1
20050137496 Walsh et al. Jul 2005 A1
20050177117 Crocker et al. Aug 2005 A1
20050182446 DeSantis Aug 2005 A1
20050192544 Wolbring et al. Sep 2005 A1
20050215956 Nerney Sep 2005 A1
20050261633 Khalaj Nov 2005 A1
20060041320 Matsuda Feb 2006 A1
20060079765 Neer Apr 2006 A1
20060089594 Landau Apr 2006 A1
20060150742 Esnouf Jul 2006 A1
20070038181 Melamud Feb 2007 A1
20070083155 Muller Apr 2007 A1
20070085767 Jung et al. Apr 2007 A1
20070100363 Dollar et al. May 2007 A1
20070167920 Hommann Jul 2007 A1
20070212385 David Sep 2007 A1
20070250010 Hohlfelder et al. Oct 2007 A1
20070270710 Frass et al. Nov 2007 A1
20080015522 Yeshurun Jan 2008 A1
20080033347 D'Arrigo et al. Feb 2008 A1
20080058706 Zhang Mar 2008 A1
20080058839 Nobles Mar 2008 A1
20080071385 Binette et al. Mar 2008 A1
20080097325 Tanaka et al. Apr 2008 A1
20080108952 Horvath et al. May 2008 A1
20080114305 Gerondale May 2008 A1
20080119797 Kim May 2008 A1
20080119876 Price et al. May 2008 A1
20080161772 Nayak Jul 2008 A1
20080167674 Bodduluri et al. Jul 2008 A1
20080188816 Shimazaki Aug 2008 A1
20080200758 Orbay et al. Aug 2008 A1
20080281278 Williams Nov 2008 A1
20090088703 Azar Apr 2009 A1
20090124996 Heneveld et al. May 2009 A1
20090125050 Dixon May 2009 A1
20090143746 Mudd et al. Jun 2009 A1
20090187118 Kim Jul 2009 A1
20090234322 Fischer Sep 2009 A1
20090240200 Heneveld et al. Sep 2009 A1
20090247953 Yeshurun Oct 2009 A1
20090259180 Choi Oct 2009 A1
20090275917 Azar Nov 2009 A1
20090287161 Traub Nov 2009 A1
20090299328 Mudd et al. Dec 2009 A1
20100006095 Woodcock Jan 2010 A1
20100030152 Lee et al. Feb 2010 A1
20100069848 Alferness Mar 2010 A1
20100100114 Berger Apr 2010 A1
20100121307 Lockard May 2010 A1
20100152675 McClintock Jun 2010 A1
20100152679 Tezel Jun 2010 A1
20100179488 Spiegel Jul 2010 A1
20100256594 Kimmell Oct 2010 A1
20100256596 Chomas Oct 2010 A1
20100280488 Pruiitt et al. Nov 2010 A1
20100282774 Greter et al. Nov 2010 A1
20100286618 Choi Nov 2010 A1
20110009808 AlGhamdi Jan 2011 A1
20110021905 Patrick et al. Jan 2011 A1
20110028910 Weber Feb 2011 A1
20110092916 Tezel et al. Apr 2011 A1
20110137286 Mudd et al. Jun 2011 A1
20110152926 Vetrecin Jun 2011 A1
20110160674 Holmes et al. Jun 2011 A1
20110172645 Moga Jul 2011 A1
20110190974 Holmes et al. Aug 2011 A1
20110202014 Mutzbauer Aug 2011 A1
20110218494 Assaf Sep 2011 A1
20110218497 Assaf Sep 2011 A1
20110230839 Bahrami et al. Sep 2011 A1
20110238038 Sefi Sep 2011 A1
20110263724 Gurtner Oct 2011 A1
20110319865 Buss Dec 2011 A1
20120041374 Lee Feb 2012 A1
20120089211 Curtis Apr 2012 A1
20120101475 Wilmot Apr 2012 A1
20120123194 Beckman May 2012 A1
20120123537 Manesis et al. May 2012 A1
20120141532 Blanda et al. Jun 2012 A1
20120150266 Shalev Jun 2012 A1
20120245629 Gross et al. Sep 2012 A1
20120259322 Fourkas Oct 2012 A1
20120265064 Bahrami et al. Oct 2012 A1
20120265171 Thorne Oct 2012 A1
20120296206 Bahrami et al. Nov 2012 A1
20130012865 Sallberg et al. Jan 2013 A1
20130018325 Schiller et al. Jan 2013 A1
20130041346 Alon Feb 2013 A1
20130096531 Estepa et al. Apr 2013 A1
20130122068 Fermanian et al. May 2013 A1
20130131632 Mudd et al. May 2013 A1
20130131633 Mudd et al. May 2013 A1
20130150826 Almohizea Jun 2013 A1
20130184648 Inou et al. Jul 2013 A1
20130184696 Fourkas Jul 2013 A1
20130197446 Gustafsson Aug 2013 A1
20130197449 Franklin et al. Aug 2013 A1
20130211374 Hetherington Aug 2013 A1
20130253289 Hadvary Sep 2013 A1
20130274655 Jennings Oct 2013 A1
20130274670 Mudd et al. Oct 2013 A1
20130280755 Hubert Oct 2013 A1
20130310763 Mudd et al. Nov 2013 A1
20140012227 Sigg et al. Jan 2014 A1
20140018770 Sutkin Jan 2014 A1
20140018835 Scherkowski Jan 2014 A1
20140066845 Mudd et al. Mar 2014 A1
20140088502 Matheny et al. Mar 2014 A1
20140088553 Hetherington Mar 2014 A1
20140114279 Klinghoffer Apr 2014 A1
20140121587 Sallberg et al. May 2014 A1
20140128685 Na May 2014 A1
20140128810 Ozawa et al. May 2014 A1
20140162901 Bahrami et al. Jun 2014 A1
20140170299 Gill Jun 2014 A1
20140228950 Whitcup et al. Aug 2014 A1
20140228971 Kim Aug 2014 A1
20140249504 Franklin et al. Sep 2014 A1
20140257190 Yue et al. Sep 2014 A1
20140309590 Bahrami et al. Oct 2014 A1
20140343481 Ignon Nov 2014 A1
20140350514 Levin Nov 2014 A1
20140350516 Schwab Nov 2014 A1
20140350517 Dominguez Nov 2014 A1
20140350518 Franklin et al. Nov 2014 A1
20140350536 Allison Nov 2014 A1
20150025459 Kimmel Jan 2015 A1
20150025563 Mosharrafa et al. Jan 2015 A1
20150119875 Fischell et al. Apr 2015 A1
20150126929 Franklin et al. May 2015 A1
20150141956 Hoffman et al. May 2015 A1
20150157809 Park et al. Jun 2015 A1
20150209265 Horne Jul 2015 A1
20150343147 Franklin et al. Dec 2015 A1
20160007990 Solish et al. Jan 2016 A1
20160058488 Fourkas Mar 2016 A1
20160095984 Franklin et al. Apr 2016 A1
20160114144 Sumida Apr 2016 A1
20160144125 Franklin May 2016 A1
20160207253 Down et al. Jul 2016 A9
20160213854 Schwab et al. Jul 2016 A1
20160263358 Unger Sep 2016 A1
20160303314 Momose Oct 2016 A1
20170080154 Mudd et al. Mar 2017 A1
20170290987 Mandaroux et al. Oct 2017 A1
Foreign Referenced Citations (90)
Number Date Country
2088857 Nov 1991 CN
2088857 Nov 1991 CN
2535071 Feb 2003 CN
200960353 Oct 2007 CN
0362484 Apr 1990 EP
0205915 Jul 1990 EP
0167662 Dec 1990 EP
0648474 Apr 1995 EP
0809968 Dec 1997 EP
1051988 Nov 2000 EP
1486218 Dec 2004 EP
1395320 Jun 2006 EP
1859827 Nov 2007 EP
1923086 May 2008 EP
2189173 May 2010 EP
2335755 Jun 2011 EP
2422832 Feb 2012 EP
2103262 Feb 2013 EP
2184016 Apr 2013 EP
2671516 Dec 2013 EP
53011 Sep 1945 FR
2622457 May 1989 FR
2857654 Jan 2005 FR
2336783 May 2003 GB
209387 Sep 2007 IN
20120007473 Jan 2012 KR
101246570 Mar 2013 KR
20130036921 Apr 2013 KR
20130130436 Dec 2013 KR
20130132196 Dec 2013 KR
20140029007 Mar 2014 KR
2286803 Nov 2006 RU
WO 90001349 Feb 1990 WO
WO 92013579 Aug 1992 WO
WO 94012228 Jun 1994 WO
WO 96025965 Aug 1996 WO
WO 97028840 Aug 1997 WO
WO 99048601 Sep 1999 WO
WO 0100190 Jan 2001 WO
WO 02055135 Jul 2002 WO
WO 2004022603 Mar 2004 WO
WO 2005095225 Oct 2005 WO
WO 2006065837 Jun 2006 WO
WO 2008086479 Aug 2006 WO
WO 2006118804 Nov 2006 WO
WO 2006133111 Dec 2006 WO
WO 2007092929 Aug 2007 WO
WO 2007140381 Dec 2007 WO
WO-2007140381 Dec 2007 WO
WO 2008019265 Feb 2008 WO
WO 2008053481 May 2008 WO
WO 2008072229 Jun 2008 WO
WO 2008079824 Jul 2008 WO
WO 2008148071 Dec 2008 WO
WO 2009003135 Dec 2008 WO
WO 2009035680 Mar 2009 WO
WO 2009091099 Jul 2009 WO
WO 2009098666 Aug 2009 WO
WO 2009158145 Dec 2009 WO
WO 2010028025 Mar 2010 WO
WO 2011016785 Feb 2011 WO
WO 2011073796 Jun 2011 WO
WO 2011075731 Jun 2011 WO
WO 2011109129 Sep 2011 WO
WO 2011109130 Sep 2011 WO
WO 2012054301 Apr 2012 WO
WO 2012054311 Apr 2012 WO
WO 2012127856 Sep 2012 WO
WO 2012172424 Dec 2012 WO
WO 2013005881 Jan 2013 WO
WO 2013054165 Apr 2013 WO
WO 2013055832 Apr 2013 WO
WO 2013082112 Jun 2013 WO
WO 2013106857 Aug 2013 WO
WO 2014026044 Feb 2014 WO
WO 2014034032 Mar 2014 WO
WO 2012174464 May 2014 WO
WO 2014064536 May 2014 WO
WO 2014189161 Nov 2014 WO
WO 2015007243 Jan 2015 WO
WO 2015020982 Feb 2015 WO
WO 2013065235 Apr 2015 WO
WO 2015064031 May 2015 WO
WO 2015105269 Jul 2015 WO
WO 2015127339 Aug 2015 WO
WO 2015149031 Oct 2015 WO
WO 2016008845 Jan 2016 WO
WO 2016022865 Feb 2016 WO
WO 2016033584 Mar 2016 WO
WO 2016033586 Mar 2016 WO
Non-Patent Literature Citations (15)
Entry
Bleyer, “SIS Facial Implant 510(k) Summary,” Cook Biotech Inc., May 2005, 1 page.
Davidenko et al., “Collagen-hyaluronic acid scaffolds for adipose tissue engineering”, ACTA Biomaterialia, vol. 6, No. 10, Oct. 1, 2010, pp. 3957-3968.
Galderma, “New Restylane Skinboosters SmartClick delivery system wins prestigious Red Dot design award,” Jul. 4, 2014, retrieved from http://www.galderma.com/News/articleType/ArticleView/articleId/64/New-Restylane-Skinboosters-SmartClick-delivery-system-wins-prestigious-Red-Dot-design-award.
Galderma, “Restylane Smart Click System Injection Device,” Mar. 2015, retrieved from http://www.red-dot-21.com/products/restylane-smart-click-system-injection-device-22169.
Hamza et al., “A new external filling device in tissue expansion,” Plastic and Reconstructive Surgery, Mar. 1998, vol. 101, No. 3, pp. 813-815.
Indian Patent Application No. 190/CHE/2002, filed Mar. 20, 2002, entitled A Subcutaneous Tissue Expander, 5 pages.
Indian Patent Application No. IN2012KO01267 for Tissue Expander, February 8, 2017, 7 pages.
International Search Report from PCT/US2016/021838, dated May 17, 2016, 3 pages.
International Search Report and Written Opinion from PCT/US2009/045831, dated Feb. 24, 2010, 14 pages.
International Search Report and Written Opinion from PCT/US2014/039265, dated Nov. 18, 2014, 18 pages.
International Search Report and Written Opinion from PCT/US2014/039266, dated Aug. 26, 2014, 13 pages.
Park et al., “Biological characterization of EDC-crosslinked collagen-hyaluronic acid matrix in dermal tissue restoration”, Biomaterials, Elsevier Science Publishers BV, vol. 24, No. 9, Apr. 1, 2003, pp. 1631-1641.
Prime Journal, “Galderma to launch two new syringes at AMWC 2014,” Mar. 2014, 4 pages.
Turtlepin, “The Painless Direct Dermal Injector” Product Information, JM Biotech Co Ltd, 2013, 18 pages.
Wang et al., “In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin.”, Archives of Dermatology, American Medical Association, US, vol. 143, No. 2, Feb. 1, 2007, pp. 155-163.
Related Publications (1)
Number Date Country
20190351146 A1 Nov 2019 US
Provisional Applications (1)
Number Date Country
61826878 May 2013 US
Continuations (2)
Number Date Country
Parent 15011897 Feb 2016 US
Child 16510808 US
Parent 14284285 May 2014 US
Child 15011897 US